Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 28

Sort by

Sort Order Select

Journal Articles

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Daniel Lopes De Menezes, Manuel Ugidos Guerrero, Arnaud Amzallag, Wendy L. See, Alberto Risueno, Charalampos Kyriakopoulos, Rajasekhar N.V.S. Suragani, Barry S. Skikne, C.L. Beach, Thomas Prebet, Maria Teresa Voso, Andre C. Schuh, Gail J. Roboz, Hartmut Döhner, Andrew H. Wei, Anita K. Gandhi

Blood (2023) 142 (Supplement 1): 1582.

https://doi.org/10.1182/blood-2023-187651

Published: 2023

Journal Articles

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Jordan Snyder, Razan Mansour, Aytaj Mammadzadeh, Hamza Hashmi, Aimaz Afrough, Omar Alkharabsheh, Barry Paul, Shebli Atrash, Muhammad Umair Mushtaq, Barry S. Skikne, Nausheen Ahmed, Al-Ola Abdallah

Blood (2023) 142 (Supplement 1): 1985.

https://doi.org/10.1182/blood-2023-187487

Published: 2023

Journal Articles

Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Priyanka Venkatesh, Ghena Khasawneh, Hamza Hashmi, Omar Alkharabsheh, Barry Paul, Barry S. Skikne, Zahra Mahmoudjafari, Nausheen Ahmed, Al-Ola Abdallah, Shebli Atrash

Blood (2023) 142 (Supplement 1): 1971.

https://doi.org/10.1182/blood-2023-188117

Published: 2023

Journal Articles

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

Mohammad Ahsen Soomro, Shebli Atrash, Aliya Rashid, William Wesson, Hamza Hashmi, Aimaz Afrough, Barry S. Skikne, Forat Lutfi, Muhammad Umair Mushtaq, Al-Ola Abdallah, Nausheen Ahmed

Blood (2023) 142 (Supplement 1): 6900.

https://doi.org/10.1182/blood-2023-180306

Published: 2023

Journal Articles

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Haitham Abdelhakim, MD, Luis M. Cortez, BS, Meizhang Li, PhD, Mitchell Braun, BS, Barry S. Skikne, MD, Tara L. Lin, MD, Neil Dunavin, MD, Andrew K Godwin, PhD

Blood (2019) 134 (Supplement_1): 3605.

https://doi.org/10.1182/blood-2019-129455

Published: 2019

Journal Articles

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Barry S. Skikne, MD, Anurag K. Singh, MD, Sunil Abhyankar, MD, Tara L. Lin, MD, Leyla Shune, MD, Neil Dunavin, MD, Ajoy L. Dias, MD, Brian McClune, DO, Abdulraheem Yacoub, MD, Clint Divine, Haitham Abdelhakim, MD, Siddhartha Ganguly, MD, Jennifer Hanses, Carol E Webb, BA, Joseph P. McGuirk, DO

Blood (2019) 134 (Supplement_1): 5743.

https://doi.org/10.1182/blood-2019-130828

Published: 2019

Journal Articles

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Tamara K Moyo, MD PhD, Justin M. Watts, MD, Barry S. Skikne, MD, Jason H. Mendler, MD PhD, Virginia M. Klimek, MD, Sheau-Chiann Chen, PhD, Run Fan, PhD MS, Ingrid A Anderson, PhD, Andrew Sochacki, MD, Stephen A. Strickland, MD, Michael T Byrne, DO, Terrence J Bradley, MD, Gregory D Ayers, MS, Sanjay R Mohan, MD MSCI, Michael R. Savona, MD

Blood (2019) 134 (Supplement_1): 4236.

https://doi.org/10.1182/blood-2019-130003

Published: 2019

Journal Articles

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Marcos de Lima, MD, Betul Oran, MDMS, Richard E. Champlin, MD, Esperanza B. Papadopoulos, MD, Sergio A. Giralt, MD, Bart L. Scott, MD, Basem M. William, MD, Joel Hetzer, PhD, Becky Hubbell, PharmD, Barry S. Skikne, MD, Charles Craddock

Blood (2017) 130 (Supplement 1): 4512.

https://doi.org/10.1182/blood.V130.Suppl_1.4512.4512

Published: 2017

Journal Articles

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Kapil Kohli, MD, Ajoy L. Dias, MD, Neil Dunavin, MD, Leyla Shune, MD, Tara L. Lin, MD, Sunil Abhyankar, MD, Anurag K. Singh, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Barry S. Skikne, MD

Blood (2017) 130 (Supplement 1): 5541.

https://doi.org/10.1182/blood.V130.Suppl_1.5541.5541

Published: 2017

Journal Articles

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

Hartmut Döhner, MD, Paresh Vyas, MD PhD, John F. Seymour, MD, Valeria Santini, MD, Richard M. Stone, MD, Mark D. Minden, MD PhD, Haifa Kathrin Al-Ali, MD, Teresa Bernal del Castillo, MD PhD, John Morrill, MS, Stephen Songer, PharmD, Jerry Weaver, PhD, Barry S. Skikne, MD, C.L. Beach, PharmD, Hervé Dombret, Prof.

Blood (2016) 128 (22): 1638.

https://doi.org/10.1182/blood.V128.22.1638.1638

Published: 2016

Journal Articles

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Guillermo Garcia-Manero, MD, Michael R. Savona, MD, Steven D. Gore, MD, Bart L. Scott, MD, Christopher R. Cogle, MD, Thomas Boyd, MD, Paul Conkling, Joel Hetzer, PhD, Qian Dong, MS, Keshava Kumar, PhD, Stacey M. Ukrainskyj, BSN, Barry S. Skikne, MD

Blood (2016) 128 (22): 905.

https://doi.org/10.1182/blood.V128.22.905.905

Published: 2016

Journal Articles

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

Aristoteles Giagounidis, MD PhD, Alan F. List, MD, Eva Hellström-Lindberg, MD PhD, Ghulam J. Mufti, MD PhD, Brigitte Schlegelberger, MD PhD, John Morrill, Chengqing Wu, PhD, Barry S. Skikne, MD, Pierre Fenaux, MD PhD, Gudrun Göhring, MD

Blood (2015) 126 (23): 1680.

https://doi.org/10.1182/blood.V126.23.1680.1680

Published: 2015

Journal Articles

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

Basem M. William, MD, Marcos de Lima, MD, Betul Oran, MD, Richard Champlin, MD, Esperanza B Papadopoulos, MD, Sergio Giralt, MD, Bart L. Scott, MD, Joel Hetzer, PhD, Xiwei Wang, PhD, Eric Laille, MS, Barry S. Skikne, MD, Charles Craddock, MDPhD

Blood (2014) 124 (21): 990.

https://doi.org/10.1182/blood.V124.21.990.990

Published: 2014

Journal Articles

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Michael R. Savona, MD, Kathryn Kolibaba, MD, Paul Conkling, MD, Edwin C. Kingsley, MD, Carlos Becerra, MD, John Morris, MD, Robert M. Rifkin, MD, Eric Laille, MS, Amy Kellerman, BA, Stacey M. Ukrainskyj, BSN,RN, Qian Dong, MS, Barry S. Skikne, MD

Blood (2014) 124 (21): 4638.

https://doi.org/10.1182/blood.V124.21.4638.4638

Published: 2014

Journal Articles

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Aristoteles Giagounidis, MD, PhD, Alan List, MD, Eva Hellström-Lindberg, MD, PhD, Mikkael A. Sekeres, MD, MS, Ghulam J. Mufti, MD, PhD, Brigitte Schlegelberger, MD, PhD, John Morrill, Chengqing Wu, Barry S. Skikne, MD, Pierre Fenaux, MD, PhD, Gudrun Göhring, MD

Blood (2013) 122 (21): 1538.

https://doi.org/10.1182/blood.V122.21.1538.1538

Published: 2013

Journal Articles

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Guillermo Garcia -Manero, MD, Michael Savona, MD, Steven D. Gore, MD, Christopher R. Cogle, MD, Paul Conkling, MD, CL Beach, PharmD, Joel Hetzer, PhD, Qian Dong, MS, Barry S. Skikne, MD

Blood (2013) 122 (21): 1554.

https://doi.org/10.1182/blood.V122.21.1554.1554

Published: 2013

Journal Articles

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Eric Laille, MS, Tao Shi, PhD, Guillermo Garcia-Manero, MD, Christopher R. Cogle, MD, Steven D. Gore, MD, Keshava J. Kumar, PhD, Barry S. Skikne, MD, Kyle J. MacBeth, PhD

Blood (2012) 120 (21): 1337.

https://doi.org/10.1182/blood.V120.21.1337.1337

Published: 2012

Journal Articles

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

John F Seymour, MB, BS, PhD, FRACP, John M. Bennett, MD, Alan F List, MD, Ghulam J. Mufti, MD, Steven D. Gore, MD, Pierre Fenaux, MD, PhD, Valeria Santini, MD, Joel Hetzer, PhD, Stephen Songer, PharmD, Barry S. Skikne, MD, C.L. Beach, PharmD

Blood (2012) 120 (21): 3808.

https://doi.org/10.1182/blood.V120.21.3808.3808

Published: 2012

Journal Articles

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease

Dalia Mahmoud, MBA, Barry S. Skikne, MD, Izabela Kucmin-Bemelmans, MSc, Cathelijne Alleman, MSc, Marja Hensen, MSc

Blood (2012) 120 (21): 3614.

https://doi.org/10.1182/blood.V120.21.3614.3614

Published: 2012

Journal Articles

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

John Powers, B.S., Eva Sahakian, Ph.D, Jason A Dubovsky, Ph.D, Tyler Farnum, Emmanuel Berchmans, B.S., Douglas G McNeel, MD, Barry S. Skikne, MD, Kyle J MacBeth, Rami S. Komrokji, MD, Javier Pinilla-Ibarz, MD, PhD

Blood (2012) 120 (21): 3828.

https://doi.org/10.1182/blood.V120.21.3828.3828

Published: 2012

NARROW

Clonal Dynamics of Gene Mutations during Oral Azacitidine Maintenance Therapy in Patients with Acute Myeloid Leukemia (AML): Outcomes from the QUAZAR AML-001 Trial

Efficacy of Daratumumab-Based Regimens in Anti-CD38 Treatment-Naïve Relapsed/Refractory Multiple Myeloma with High-Risk Cytogenetics

Outcomes of Vdpace for Relapsed/Refractory Multiple Myeloma in the Era of Daratumumab Based Therapy

Outcomes Multiple Myeloma Patients Progressing after BCMA-Directed Chimeric Antigen Receptor T Cell (CART) Therapy

LAG3 Inhibition Decreases AML-Induced Immunosuppression and Improves T Cell-Mediated Killing

Conditioning Regimen Intensity May Affect Outcome in MDS Patients Undergoing Allogeneic Stem Cell Transplantation, Depending on MDS Subgroup

Preliminary Results from a Phase II Study of the Combination of Pevonedistat and Azacitidine in the Treatment of MDS and MDS/MPN after Failure of DNA Methyltransferase Inhibition

Final Analysis of the Phase I/II Study of CC-486 (Oral Azacitidine) Maintenance Therapy after Allogeneic Stem Cell Transplantation (Allo-SCT) in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS)

Chemotherapy-Refractory Acute Myeloid Leukemia and Outcomes after Allogeneic Stem Cell Transplantation—a Single Center Analysis

Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

CC-486 (Oral Azacitidine) in Patients with Hematological Malignancies Who Had Received Prior Treatment with Injectable Hypomethylating Agents (HMAs): Results from Phase 1/2 CC-486 Studies

Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies

CC-486 (Oral Azacitidine) Following Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) in Patients with Myelodysplastic Syndromes (MDS) or Acute Myeloid Leukemia (AML)

CC-486 in Patients with Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), or Chronic Myelomonocytic Leukemia (CMML): Safety, Tolerability, and Response

Impact Of The Proportion Of Metaphases With Isolated Del(5q) On Clinical Outcomes In Lenalidomide (LEN)-Treated Patients With IPSS Low-/Int-1-Risk Myelodysplastic Syndromes (MDS) In MDS-003 and MDS-004

Hematologic Response To Oral Azacitidine (CC-486) In Subjects With WHO-Defined RAEB-1 Or RAEB-2 Myelodysplastic Syndromes (MDS)

Extended Dosing of Oral Azacitidine (CC-486) for 14 and 21 Days Provides More Effective Methylation Reversal Than a 7-Day Schedule

Bone Marrow Hypocellularity Does Not Impair the Tolerability or Efficacy of Azacitidine (AZA) in Patients with Higher-Risk Myelodysplastic Syndromes Treated in the AZA-001 Study

Overall Economic Burden of Total Treatment Costs in Acute Myeloid Leukemia throughout the Course of the Disease

Inducible Expression of Cancer Testis Antigens in Myelodysplastic Syndrome (MDS) Patients Following Treatment with an Oral 5-Azacytidine

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only